Details

Autor(en) / Beteiligte

• Helmink, Marga A G
• Peters, Sanne A E
• Westerink, Jan
• Harris, Katie
• Tillmann, Taavi
• Woodward, Mark
• van Sloten, Thomas T
• van der Meer, Manon G
• Teraa, Martin
• Dorresteijn, Jannick A N
• Ruigrok, Ynte M
• Visseren, Frank L J
• Hageman, Steven H J
• Cramer, M J
• Nathoe, H M
• van der Meer, M G
• de Borst, G J
• Teraa, M
• Bots, M L
• van Smeden, M
• Emmelot-Vonk, M H
• de Jong, P A
• Lely, A T
• van der Kaaij, N P
• Kappelle, L J
• Ruigrok, Y M
• Verhaar, M C
• Dorresteijn, J A N
• Visseren, F L J

Titel

Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model

Ist Teil von

• European journal of preventive cardiology, 2024-10, Vol.31 (14), p.1671-1678

Erscheinungsjahr

2024

Beschreibungen/Notizen

• Abstract Aims Identifying patients with established cardiovascular disease (CVD) who are at high risk of type 2 diabetes (T2D) may allow for early interventions, reducing the development of T2D and associated morbidity. The aim of this study was to develop and externally validate the CVD2DM model to estimate the 10-year and lifetime risks of T2D in patients with established CVD. Methods and results Sex-specific, competing risk-adjusted Cox proportional hazard models were derived in 19 281 participants with established CVD and without diabetes at baseline from the UK Biobank. The core model’s pre-specified predictors were age, current smoking, family history of diabetes mellitus, body mass index, systolic blood pressure, fasting plasma glucose, and HDL cholesterol. The extended model also included HbA1c. The model was externally validated in 3481 patients from the UCC-SMART study. During a median follow-up of 12.2 years (interquartile interval 11.3–13.1), 1628 participants with established CVD were diagnosed with T2D in the UK Biobank. External validation c-statistics were 0.79 [95% confidence interval (CI) 0.76–0.82] for the core model and 0.81 (95% CI 0.78–0.84) for the extended model. Calibration plots showed agreement between predicted and observed 10-year risk of T2D. Conclusion The 10-year and lifetime risks of T2D can be estimated with the CVD2DM model in patients with established CVD, using readily available clinical predictors. The model would benefit from further validation across diverse ethnic groups to enhance its applicability. Informing patients about their T2D risk could motivate them further to adhere to a healthy lifestyle.